HDAC9 and breast carcinoma: Differently from pan-HDAC inhibitors (such as SAHA), entinostat (MS-275) selectively inhibits class I HDACs (HDAC 1–3) and has been extensively studied for solid tumors, such as breast cancer (Knipstein and Gore, 2011; Trapani et al., 2017).